These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26879839)

  • 1. Long-term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia.
    Saccà F; Puorro G; Marsili A; Antenora A; Pane C; Casali C; Marcotulli C; Defazio G; Liuzzi D; Tatillo C; Cambriglia DM; Schiano di Cola G; Giuliani L; Guardasole V; Salzano A; Ruvolo A; De Rosa A; Cittadini A; De Michele G; Filla A
    Mov Disord; 2016 May; 31(5):734-41. PubMed ID: 26879839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit.
    Saccà F; Piro R; De Michele G; Acquaviva F; Antenora A; Carlomagno G; Cocozza S; Denaro A; Guacci A; Marsili A; Perrotta G; Puorro G; Cittadini A; Filla A
    Mov Disord; 2011 Mar; 26(4):739-42. PubMed ID: 21506154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
    Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
    J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial.
    Mariotti C; Fancellu R; Caldarazzo S; Nanetti L; Di Bella D; Plumari M; Lauria G; Cappellini MD; Duca L; Solari A; Taroni F
    Mov Disord; 2012 Mar; 27(3):446-9. PubMed ID: 22411849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss.
    Arroliga AC; Guntupalli KK; Beaver JS; Langholff W; Marino K; Kelly K
    Crit Care Med; 2009 Apr; 37(4):1299-307. PubMed ID: 19242343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial.
    Keown PA; Churchill DN; Poulin-Costello M; Lei L; Gantotti S; Agodoa I; Gitlin M; Gandra SR; Mayne TJ
    Hemodial Int; 2010 Apr; 14(2):168-73. PubMed ID: 20345390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
    Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
    Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
    J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
    Shasha D; George MJ; Harrison LB
    Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia.
    Nachbauer W; Wanschitz J; Steinkellner H; Eigentler A; Sturm B; Hufler K; Scheiber-Mojdehkar B; Poewe W; Reindl M; Boesch S
    Mov Disord; 2011 Aug; 26(10):1935-8. PubMed ID: 21692115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
    Wright JR; Ung YC; Julian JA; Pritchard KI; Whelan TJ; Smith C; Szechtman B; Roa W; Mulroy L; Rudinskas L; Gagnon B; Okawara GS; Levine MN
    J Clin Oncol; 2007 Mar; 25(9):1027-32. PubMed ID: 17312332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem.
    Glaspy J
    Semin Hematol; 1997 Jul; 34(3 Suppl 2):20-6. PubMed ID: 9253780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
    Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
    Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study.
    Scott SN; Boeve TJ; McCulloch TM; Fitzpatrick KA; Karnell LH
    Laryngoscope; 2002 Jul; 112(7 Pt 1):1221-9. PubMed ID: 12169903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early epoetin alfa treatment in children with solid tumors.
    Zoubek A; Kronberger M
    Med Pediatr Oncol; 2002 Oct; 39(4):459-62. PubMed ID: 12203664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
    Pockros PJ; Shiffman ML; Schiff ER; Sulkowski MS; Younossi Z; Dieterich DT; Wright TL; Mody SH; Tang KL; Goon BL; Bowers PJ; Leitz G; Afdhal NH;
    Hepatology; 2004 Dec; 40(6):1450-8. PubMed ID: 15565613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.